Polyrizon Completes Manufacturing Upscaling Milestone For Its Proprietary Nasal-Spray Product Platform

Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced the successful completion of a major manufacturing upscaling milestone for its proprietary nasal-spray product platform. This achievement marks a critical step toward supporting upcoming clinical and regulatory activities, as well as potential commercial readiness in the future.

During the upscaling process, Polyrizon and its manufacturing partner successfully transitioned from small-batch laboratory production to a larger-scale, controlled manufacturing run designed to validate key parameters of PL-14 formulation. The milestone demonstrates that the PL-14 formulation can be reliably produced at increased batch volumes while maintaining high-quality specifications. The manufacturing process is set to support the clinical trial material (CTM) needed for Polyrizon's clinical trial, which is expected to commence in 2026, offering high-quality and compliant production in line with USA and European regulatory standards.

PL-14 is Polyrizon's innovative intranasal protective spray designed to create a fast-acting, moisturizing barrier inside the nasal cavity, helping to trap, isolate, and neutralize airborne allergens before they reach the mucosa. Based on a proprietary bio-adhesive formulation developed by Polyrizon's R&D team, PL-14 is engineered to provide extended protection, and offers a non-pharmacological solution for allergy sufferers in environments with high allergen exposure.